$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Efficacy, safety and tolerability of larotrectinib in the treatment of lung cancer
2025-10-19 11:44:20
Check Details
Effect data of pozitinib in the treatment of NSCLC (non-small cell lung cancer)_ Kanghule
2025-10-19 11:44:20
Check Details
Larotinib has significant effect in treating NTRK mutant lung cancer
2025-10-19 11:44:20
Check Details
Efficacy data and adverse reactions of larotrectinib in the treatment of lung cancer
2025-10-19 11:44:20
Check Details
Can EGFR gene-mutated lung cancer be treated with pozitinib?
2025-10-19 11:44:20
Check Details
Targeted drug for EGFR mutated lung cancer: Pozitinib (Pozitinib)_ Kanghule
2025-10-19 11:44:20
Check Details
Analysis of the efficacy and adverse reactions of pozitinib in the treatment of lung cancer
2025-10-19 11:44:20
Check Details
How much does a box of targeted drug crizotinib cost after it is included in medical insurance?
2025-10-19 11:44:20
Check Details
How much does a box of the lung cancer targeted drug Bozitinib cost? Where can I buy it?
2025-10-19 11:44:20
Check Details
Study of Crizotinib (Xalkori) in Patients with Brain Metastases
2025-10-19 11:44:20
Check Details
The cost for a patient to treat lung cancer with pozitinib for one month
2025-10-19 11:44:20
Check Details
Ceritinib is effective in first-line treatment of crizotinib-resistant lung cancer patients
2025-10-19 11:44:20
Check Details
1
2
...
3908
3909
3910
3911
3912
3913
3914
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
2
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
3
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
4
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
5
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
6
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
7
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
8
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
9
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
10
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
11
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor
12
Alpelisib: From Breast Cancer to PIK3CA-Related Overgrowth Spectrum